Most Read Articles
Jairia Dela Cruz, 01 Jan 2020
A novel low-intensity pulsed ultrasound (LIPUS) holds therapeutic potential in patients with mild-to-moderate erectile dysfunction (ED), restoring erectile function without deleterious consequences—a benefit attributed to the mechanical force of the device that can reverse the pathological changes in the corpus cavernosum, as shown in a recent study.

Update on ADT: Degarelix shows promise in patients with advanced prostate cancer and CVD

26 Nov 2019
The incidence of prostate cancer (PC) and cardiovascular disease (CVD) typically increases with age; therefore, the choice of treatment for PC should take into account a patient’s underlying cardiovascular conditions. In this interview, Professor Laurence Klotz shared his take on androgen deprivation therapy (ADT) options for patients with prostate cancer who are at-risk of CV events.

Related MIMS Drugs

Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 01 Jan 2020
A novel low-intensity pulsed ultrasound (LIPUS) holds therapeutic potential in patients with mild-to-moderate erectile dysfunction (ED), restoring erectile function without deleterious consequences—a benefit attributed to the mechanical force of the device that can reverse the pathological changes in the corpus cavernosum, as shown in a recent study.